Research Topics
| D ErkanSummaryAffiliation: Hospital for Special Surgery Country: USA Publications
| Collaborators
|
Detail Information
Publications
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndromeDoruk Erkan
Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York, USA
Arthritis Rheum 65:464-71. 2013..The secondary objectives were to evaluate the effect of rituximab on the aPL profile and to evaluate the efficacy of rituximab treatment for non-criteria manifestations of APS...- APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal NetworkingD Erkan
Barbara Volcker Center for Women and Rheumatic Diseases, New York, New York, USA
Lupus 21:695-8. 2012.... - New approaches for managing antiphospholipid syndromeDoruk Erkan
The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
Nat Clin Pract Rheumatol 5:160-70. 2009..Potential new approaches for the management of persistently aPL-positive patients include hydroxychloroquine, statins, rituximab, complement inhibition, and other targeted therapies that have been effective in experimental APS models... 
Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapyDoruk Erkan
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
Arthritis Rheum 47:285-90. 2002..To conduct a pilot study to identify rheumatologists' treatment preferences for first-line rheumatoid arthritis (RA) therapy and determine whether pharmacoeconomic variables modify physician choice(s)...- Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchersD Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, NY 10021, USA
Rheumatology (Oxford) 47:iii23-7. 2008..However, the management of pregnant aPL-positive women still displays several open questions... - Non-criteria manifestations of antiphospholipid syndromeD Erkan
Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
Lupus 19:424-7. 2010..This brief review may help physicians in the management of the non-criteria manifestations of aPL... - Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?D Erkan
Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA
Lupus 19:613-9. 2010..Furthermore, high-titer abeta(2)GPI positivity may further increase the prevalence of non-criteria aPL manifestations in moderate- or high-titer aCL-positive patients... - Antiphospholipid Syndrome Clinical Research Task Force reportD Erkan
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
Lupus 20:219-24. 2011..An international collaborative meeting to formulate a good research question using 'FINER' (Feasible; Interesting; Novel; Ethical; and Relevant) criteria took place in November 2010... - Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individualsDoruk Erkan
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
Arthritis Rheum 56:2382-91. 2007.... - Risk quantification in antiphospholipid syndromeDoruk Erkan
Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, USA and Hospital for Special Surgery, New York, NY, USA and Weill Medical College of Cornell University, New York, NY, USA
Womens Health (Lond Engl) 6:179-82. 2010.... 
Real world experience with antiphospholipid antibody tests: how stable are results over time?D Erkan
Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 E70th Street, New York, NY 10021, USA
Ann Rheum Dis 64:1321-5. 2005....- Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?S S Pierangeli
Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
Lupus 19:475-85. 2010.... - A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndromeD Erkan
Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York 10021, SA
Rheumatology (Oxford) 41:924-9. 2002..Use of aspirin and/or hydroxychloroquine may be protective against thrombosis in asymptomatic aPL-positive individuals... - Cardiac involvement in the antiphospholipid syndromeF Tenedios
Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
Lupus 14:691-6. 2005..The heterogeneity of APS clinical manifestations is likely linked to the varied effects that aPL can induce on endothelial cells and to the different functions that endothelial cells display depending on the anatomic localization... - Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndromeD Alpert
Department of Rheumatology, Hospital for Special Surgery, New York, USA
Ann Rheum Dis 67:395-401. 2008..To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in systemic lupus erythematosus (SLE) patients with and without antiphospholipid antibodies (aPL)... - Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalitiesY Yazici
Hospital for Special Surgery, Weill Medical College of Cornell University, USA
Clin Exp Rheumatol 23:517-20. 2005..To determine the frequency of liver function tests (LFT) abnormalities associated with methotrexate (MTX) use in the treatment of rheumatoid arthritis (RA)... - Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus reportM Lockshin
Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY 10021, USA
Lupus 12:518-23. 2003..Pulmonary hypertension: the Committee recommends intensive anticoagulation with warfarin and clinical trials of bosentan, epoprostenol and other new agents... - Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndromeD Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
Lupus 11:215-20. 2002..These associations were not found with antiprothrombin antibodies. In conclusion dual autoantibodies to beta2GPI and protein S are associated with increased history of thrombosis in the antiphospholipid syndrome... - Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world"Y Yazici
Division of Rheumatology, The Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
Ann Rheum Dis 61:638-40. 2002..To determine the incidence of disease flare during the first year of etanercept treatment for 88 patients with rheumatoid arthritis (RA) and compare it with the incidence of flare in those same patients in the year before etanercept use... - Primary antiphospholipid syndrome: functional outcome after 10 yearsD Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
J Rheumatol 27:2817-21. 2000..To analyze the 10 year functional outcome of primary antiphospholipid syndrome (APS)... - Reporting consistency in systemic lupus erythematosus patients: how reliable are patient histories?Y Yazici
Lupus 11:46-8. 2002..Our study suggests that, even though SLE patients are generally consistent reporters of certain aspects of their histories, family history information provided is frequently not consistent with previous reporting... - Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosusDeborah Alpert
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
Nat Clin Pract Rheumatol 3:473-8; quiz, 2nd following 478. 2007..During this time she participated in an observational study to evaluate risk factors for the development of subclinical atherosclerosis in patients with SLE... - Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse eventsYusuf Yazici
The Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
Arthritis Rheum 48:2769-72. 2003.... - Cardiac manifestations in the antiphospholipid syndromeFelicia Tenedios
Hospital for Special Surgery, Department of Rheumatology, Weill Medical College of Cornell University, 535 East 70 th Street, New York, NY 10021, USA
Rheum Dis Clin North Am 32:491-507. 2006..aPL may be associated with accelerated atherosclerosis in APS patients. Valve disease is the most important and most common cardiac manifestation of APS. The precise mechanism by which valves become deformed is not yet fully known... - Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literatureD Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
Lupus 8:560-4. 1999..In both patients, bleeding stopped promptly and coagulation studies improved significantly with high dose corticosteroids. We discuss the pathogenesis, diagnosis and management of LAC-HPS in patients with SLE... - Long term outcome of catastrophic antiphospholipid syndrome survivorsD Erkan
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
Ann Rheum Dis 62:530-3. 2003..The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown... - Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendationsDoruk Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
J Rheumatol 29:843-9. 2002.... - The role of cardiac magnetic resonance imaging in antiphospholipid syndromeDoruk Erkan
Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA
J Rheumatol 29:2658-9. 2002 - VATER association: is it recognised by rheumatologists?D Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
Clin Rheumatol 20:128-31. 2001..These anomalies may become evident later in life. Therefore, in a rheumatologic practice, when evaluating patients with back pain and vertebral anomalies, one should become familiar with the varied manifestations of VATER association... - Assessment of the 2006 revised antiphospholipid syndrome classification criteriaMala Kaul
Weill Medical College of Cornell University, New York, NY, USA
Ann Rheum Dis 66:927-30. 2007..To analyse antiphospholipid (aPL) antibody-positive patients using the 2006 revised antiphospholipid syndrome (APS) classification criteria... - How much warfarin is enough in APS related thrombosis?Doruk Erkan
Hospital for Special Surgery, Weill Cornell Medical College, Barbara Volcker Center, 535 E 70th Street, New York, NY 10021, USA
Thromb Res 114:435-42. 2004.... - Is Hughes-Stovin syndrome Behçet's disease?D Erkan
Department of Rheumatology, Hospitalfor Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Exp Rheumatol 22:S64-8. 2004.... - Protein-losing enteropathy in systemic lupus erythematosus: report of a severe, persistent case and review of pathophysiologyY Yazici
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
Lupus 11:119-23. 2002..We report a severe and resistant case of PLE, discuss pathophysiology and possible role of cytokines in the disease process. We also present a review of the current literature... - The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literature and management strategiesDoruk Erkan
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
Curr Rheumatol Rep 4:379-86. 2002..Some data suggest that LDA might be effective against future non-gravid vascular thrombosis in patients with APS and a history of only pregnancy morbidity... - Antiphospholipid syndromeDoruk Erkan
The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, USA
Curr Opin Rheumatol 18:242-8. 2006..To review the recently published studies that can guide physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients... - Diagnostic usefulness of 3 dimensional gadolinium enhanced magnetic resonance venography in antiphospholipid syndromeHale Erel
Division of Radiology, Hospital for Special Surgery, New York, NY 10021, USA
J Rheumatol 29:1338-9. 2002 - The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupusUlas D Bayraktar
Interfaith Medical Center, Brooklyn, New York, USA
J Rheumatol 34:346-52. 2007..To compare the clinical spectrum of patients with primary catastrophic antiphospholipid syndrome (P-CAPS) to those with systemic lupus erythematosus-associated CAPS (SLE-CAPS)... - New treatments for antiphospholipid syndromeDoruk Erkan
The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, NY 10021, USA
Rheum Dis Clin North Am 32:129-48, x. 2006..It is highly possible that the current "antithrombotic" approach to patients who are aPL-positive will be replaced by a "more specifically targeted, anti-inflammatory or immunomodulatory" approach in the future... - Catastrophic antiphospholipid syndrome: where do we stand?Doruk Erkan
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 48:3320-7. 2003 - Therapeutic and prognostic considerations in catastrophic antiphospholipid syndromeDoruk Erkan
The Barbara Volcker Center for Women and Rheumatic Disease, Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 E70th Street, New York, NY 10021, USA
Autoimmun Rev 6:98-103. 2006..This article reviews the therapeutic and prognostic controversies that were addressed during the 1st International Symposium on CAPS... - What is antiphospholipid syndrome?Doruk Erkan
Department of Rheumatolopgy, Hospital for Special Surgery, 535 E 70th Street, New York, NY 10021, USA
Curr Rheumatol Rep 6:451-7. 2004.... - New insights into pregnancy-related complications in systemic lupus erythematosusDoruk Erkan
Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
Curr Rheumatol Rep 5:357-63. 2003.... - Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et alDoruk Erkan
Clin Rheumatol 22:493. 2003 - Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and PincusYusuf Yazici
Arthritis Rheum 48:3611; author reply 3613-5. 2003 - Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?Yusuf Yazici
J Rheumatol 29:1586-9. 2002 - Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulatorDoruk Erkan
Department of Hematology and Oncology, University of Pittsburgh, Pennsylvania, USA
J Rheumatol 29:2006-11. 2002..The pathogenesis may involve concurrent impairment of different VEC functions. Achieving remission may require a polypharmacologic approach, represented here by use of defibrotide... - Challenges in bringing the bench to bedside in drug development for SLEJoan T Merrill
Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street Oklahoma City, Oklahoma 73104, USA
Nat Rev Drug Discov 3:1036-46. 2004..With the current burst of drug discovery and increased public awareness of SLE, the impetus to overcome these obstacles has never been greater... - Treatment of the antiphospholipid syndromeMichael D Lockshin
N Engl J Med 349:1177-9. 2003 - Lupus and thrombosisDoruk Erkan
J Rheumatol 33:1715-7. 2006 - Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patientsSilvia Bucciarelli
, , Barcelona, Catalonia, Spain
Arthritis Rheum 54:2568-76. 2006..The presence of SLE was related to a higher mortality rate. According to the results of the present study, ACs plus CS plus PE should be the first line of therapy in patients with CAPS... - Warfarin in antiphospholipid syndrome--time to explore new horizonsDoruk Erkan
J Rheumatol 32:208-12. 2005 - Catastrophic antiphospholipid syndromeSetu K Vora
Pulmonary Physicians of Norwich, Norwich, Connecticut, USA
J Intensive Care Med 21:144-59. 2006..This article reviews the current information on the etiopathogenesis, clinical manifestations, diagnosis, management, and prognosis of catastrophic antiphospholipid syndrome...